Buprenorphine/naloxone pediatric ingestion: Exposure rates differ between film and tablet formulations

December 19, 2014

Aims: Buprenorphine ingestion can cause life-threatening poisoning in young children. Previous reports have found that film formulations are associated with lower pediatric exposure rates than tablet formulations. The purpose of this study is to determine whether these relationships are stable over time. (Source: Drug and Alcohol Dependence)

Read the full article →

Differences between heroin and non-prescription opioid analgesics users in treatment-seeking opioid-dependent young adults

December 19, 2014

Aims: The purpose of this study was to evaluate the demographic, infectious disease status and clinical severity of dependence among heroin users compared to non-prescribed opioid analgesic users in a group of opioid dependent young adults seeking treatment with buprenorphine/naloxone. (Source: Drug and Alcohol Dependence)

Read the full article →

Feasibility of very low dose naltrexone and buprenorphine transition from opioid use to extended-release naltrexone

December 19, 2014

Aims: The approval of extended release injectable naltrexone suspension (XR-NTX) has introduced a new option for treating opioid addiction, but the absence of physiological opioid dependence is a necessary and challenging first step for starting therapy. Outpatient detoxification gives poor results and inpatient detoxification is either unavailable or too brief for the physiological effects of […]

Read the full article →

Primary care buprenorphine detoxification vs. maintenance for prescription opioid dependence

December 19, 2014

Aims: The favorable clinical characteristics and improved treatment outcomes for prescription opioid dependent (POD) patients, and modest severity of withdrawal symptoms with buprenorphine/naloxone (bup/nx), have led physicians to offer detoxification with bup/nx for POD patients. We sought to determine whether bup/nx stabilization followed by detoxification (DTX) or maintenance (MTN) leads to greater reduction in illicit […]

Read the full article →

Buprenorphine/naloxone abuse and diversion: Film rates are less than tablet rates

December 19, 2014

This study extends the comparison of diversion and abuse rates between buprenorphine sublingual formulations. (Source: Drug and Alcohol Dependence)

Read the full article →

Cognitive behavioral therapy improves treatment outcome for prescription opioid users in primary care based buprenorphine/naloxone treatment

December 19, 2014

Aims: To assess whether response to Cognitive Behavioral Therapy (CBT) differed between primarily prescription opioid users (POU) and primarily heroin users (HU) receiving primary care buprenorphine/naloxone (BUP) treatment with physician management (PM). (Source: Drug and Alcohol Dependence)

Read the full article →

Medicaid budget impact of generic buprenorphine/naloxone tablet

December 19, 2014

Aims: The buprenorphine/naloxone (Bup/Nal)combination for the treatment of opioid dependence is available in two forms – sublingual film and tablet. Recent studies demonstrated that treatment with film leads to improved treatment retention and lower healthcare costs. In March 2013 generic tablets appeared on the market. A budget impact model was built to compare health care […]

Read the full article →

Dose and other factors associated with decreased pain intensity among patients initiating buprenorphine/naloxone

December 19, 2014

We examined dose and other factors associated with decreased pain intensity among patients initiating BUP/NX for OUD. (Source: Drug and Alcohol Dependence) MedWorm Sponsor Message: Directory of the best January Sales in the UK. Find the best Christmas presents too.

Read the full article →

Zubsolv comparable to Suboxone in retention, cravings: Study

December 18, 2014

(Source: Alcoholism and Drug Abuse Weekly) MedWorm Sponsor Message: Directory of the best January Sales in the UK. Find the best Christmas presents too.

Read the full article →

Liver enzyme levels in adolescent patients treated with buprenorphine and additional psychotropic agents.

December 14, 2014

CONCLUSIONS: Buprenorphine/naloxone was well tolerated in most adolescent patients, besides clinically nonsignificant liver enzyme elevations. Psychotropic medications may have been associated with the liver enzyme changes early in the course of treatment. Nevertheless, given the relatively small number of adolescents studied to date with buprenorphine/naloxone, additional studies evaluating liver enzymes in young patients receiving buprenorphine/naloxone […]

Read the full article →

← Previous Entries

Next Entries →